IM Cannabis (IMCC) Cost of Revenue (2020 - 2026)

IM Cannabis' Cost of Revenue history runs 7 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 16.08% year-over-year to $5.3 million in Q1 2026; TTM through Mar 2026 was $31.3 million, a 2.25% decrease from a year earlier, with the FY2025 full-year figure at $32.3 million, down 2.98% from the prior year.
• Cost of Revenue declined to $5.3 million in Q1 2026 per IMCC's latest filing, from $11.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $11.2 million in Q4 2025 and bottomed at $5.3 million in Q1 2026.
• The 5-year median for Cost of Revenue is $7.6 million (2024), against an average of $7.6 million.
• Across the five-year window, Cost of Revenue surged 82.38% in 2022 and sank 34.19% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $8.6 million in 2022, then retreated by 18.13% to $7.0 million in 2023, then increased by 8.36% to $7.6 million in 2024, then jumped by 46.68% to $11.2 million in 2025, then sank by 52.68% to $5.3 million in 2026.
• Per Business Quant, the three latest IMCC Cost of Revenue figures stand at $5.3 million (Q1 2026), $11.2 million (Q4 2025), and $8.1 million (Q3 2025).